Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 10 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 8557806

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted
  2. US 8557822

    Carboxamide, sulfonamide and amine compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted
  3. US 8546433

    Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

    Rigel Pharmaceuticals, Inc. · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted
  4. US 8546398

    Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted
  5. US 8530466

    Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

    Rigel Pharmaceuticals, Inc. · Granted Sep 10, 2013 · Expires Sep 5, 2033

    granted
  6. US 8530656

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Sep 10, 2013 · Expires Sep 5, 2033

    granted
  7. US 8524901

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Sep 3, 2013 · Expires Aug 29, 2033

    granted
  8. US 8518937

    Pyrimidinediamine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted
  9. US 8507675

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Aug 13, 2013 · Expires Aug 8, 2033

    granted
  10. US 8497279

    Treatment for discoid lupus

    Rigel Pharmaceuticals, Inc. · Granted Jul 30, 2013 · Expires Jul 25, 2033

    granted
  11. US 8492373

    Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jul 23, 2013 · Expires Jul 18, 2033

    granted
  12. US 8486935

    Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine

    Rigel Pharmaceuticals, Inc. · Granted Jul 16, 2013 · Expires Jul 11, 2033

    granted
  13. US 8481521

    Methods of treating cell proliferative disorders

    Rigel Pharmaceuticals, Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted
  14. US 8476263

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 2, 2013 · Expires Jun 27, 2033

    granted
  15. US 8445485

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted May 21, 2013 · Expires May 16, 2033

    granted
  16. US 8431594

    Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted
  17. US 8420659

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Apr 16, 2013 · Expires Apr 11, 2033

    granted
  18. US 8415365

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted
  19. US 8410093

    Cycloalkyl substituted pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Apr 2, 2013 · Expires Mar 28, 2033

    granted
  20. US 8410266

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Apr 2, 2013 · Expires Mar 28, 2033

    granted
  21. US 8399472

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Mar 19, 2013 · Expires Mar 14, 2033

    granted
  22. US 8394951

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted
  23. US 8389557

    Triazole derivatives useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted
  24. US 8389515

    2,4-pyrimidinediamine compounds and prodrugs and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted